niche

Hair Relaxer Lawsuit Black Women

Preparing your case review…
Written By
People's Justice Legal Research Team

Why Black Women Are Disproportionately Affected

Black women are the primary consumers of chemical hair relaxers in the United States. Approximately 60% of participants who reported using straighteners in the NIH Sister Study were self-identified Black women. Black women use these products more frequently, begin use at younger ages (often in childhood), and consequently accumulate higher lifetime EDC exposure than any other demographic group.

The Marketing Machine

For decades, hair relaxer manufacturers aggressively marketed their products to Black women and girls through advertising in Black-owned media: Ebony, Jet, Essence, BET. Product names ("Dark & Lovely," "African Pride," "Just for Me") explicitly targeted Black consumers. Products were positioned as necessities for professional appearance — reinforcing discriminatory beauty standards that penalized natural Black hair.

Workplace Discrimination and Coercive Pressure

The CROWN Act movement exists because Black women faced documented employment and educational consequences for wearing natural hair. This discrimination created a coercive environment where chemical straightening felt mandatory for career advancement. The litigation argues that hair relaxer manufacturers profited from this systemic pressure while hiding the cancer risks of their products.

The Uterine Cancer Mortality Disparity

Black women die of uterine cancer at twice the rate of white women — one of the largest racial cancer mortality disparities documented in the United States. The hair relaxer litigation raises a pointed question: how much of this disparity was caused by an industry that marketed carcinogen-containing products specifically to Black women without disclosing the cancer risk?

Environmental Justice Framework

The Environmental Working Group found that personal care products marketed to Black women contain significantly higher concentrations of hazardous chemicals than mainstream products. The hair relaxer litigation is part of a broader environmental justice movement recognizing that communities of color bear disproportionate exposure to toxic chemicals — not by coincidence, but through corporate marketing decisions.

Research & Evidence

Scientific Evidence

Hair Relaxer Use and Risk of Uterine Cancer in the Black Women's Health Study

Bertrand KA, Coogan PF, Palmer JR (2023). Environmental Research

View on PubMed

Use of Straighteners and Other Hair Products and Incident Uterine Cancer

Chang CJ, O'Brien KM, Keil AP, Gaston SA, Jackson CL, Sandler DP, White AJ (2022). Journal of the National Cancer Institute

View on PubMed

Use of Hair Products in Relation to Ovarian Cancer Risk

White AJ, Sandler DP, et al. (2021). Carcinogenesis

View on PubMed
FAQ

Frequently Asked Questions

See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
See details below.
Related Topics

Related Pages

Hair Relaxer Uterine Cancer

Uterine cancer is the primary injury in the hair relaxer litigation. The NIH Sister Study found a 155% increased risk (HR 2.55) for frequent users. Approximately 67,000 Americans are diagnosed with uterine cancer annually.

uterine-cancerendometrial-cancersister-study
Learn more

Hair Relaxer Ovarian Cancer

The Sister Study found hair relaxer users face a 2.19x increased risk of ovarian cancer. Ovarian cancer is often called the "silent killer" because symptoms are vague until advanced stages, making early detection difficult.

ovarian-cancersilent-killerphthalates
Learn more

Hair Relaxer Endometriosis

Chemical hair relaxers contain EDCs linked to endometriosis — a painful condition where uterine-like tissue grows outside the uterus. Phthalates and parabens in relaxers promote endometrial implant growth through estrogen mimicry.

endometriosispelvic-paininfertility
Learn more

Hair Relaxer Settlement Amounts

No hair relaxer cases have settled or gone to trial yet. Attorney estimates project $90,000–$1,000,000+ depending on injury type and severity. Bellwether trials expected in 2027 will establish actual case values.

settlement-amountsprojected-valuesbellwether
Learn more

L'Oréal Hair Relaxer Lawsuit

L'Oréal is the primary defendant in the hair relaxer MDL through its subsidiary SoftSheen-Carson, maker of Dark & Lovely and Optimum Care. L'Oréal is the world's largest beauty company with €38+ billion in annual revenue.

lorealsoftsheen-carsondark-and-lovely
Learn more

Revlon Dark and Lovely Lawsuit

Revlon is a defendant in the hair relaxer MDL despite filing bankruptcy in 2022. Revlon maintains insurance coverage and allocated ~$44 million for hair relaxer claims in its reorganization plan. Products include Creme of Nature and Revlon Realistic.

revloncreme-of-naturebankruptcy
Learn more

Hair Relaxer Chemical Exposure

Hair relaxers contain at least 45 endocrine-disrupting chemicals across 10 chemical classes. 84% of these chemicals are NOT listed on product labels. The chemicals enter the body through the scalp, whose protective barrier is compromised by the relaxing process itself.

chemical-exposureedcphthalates
Learn more
Parent Case

Hair Relaxer Cancer Lawsuits Lawsuit

Chemical hair relaxers and straighteners contain endocrine-disrupting chemicals (EDCs) — including phthalates, parabens, formaldehyde, and cyclosiloxanes — that mimic estrogen and disrupt the hormonal system. The NIH/NIEHS Sister Study (2022) found that women who frequently used these products faced more than double the risk of uterine cancer. Over 14,700 lawsuits are consolidated in MDL 3060 in the Northern District of Illinois, with bellwether trials expected in 2027. The litigation disproportionately affects Black women, who were the primary marketing target and comprise approximately 60% of affected users.

View full case overview